Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

57 results about "Protein kinase modulator" patented technology

Protein kinase modulators and methods of use

InactiveUS20060211709A1Determine effectBiocideOrganic chemistryArylDisease
Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
Owner:EXELIXIS INC

Novel tricyclic protein kinase modulators

The invention provides compounds that inhibit CK2 and / or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
Owner:SENHWA BIOSCIENCES INC

Protein kinase modulators

The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and / or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
Owner:SENHWA BIOSCIENCES INC

Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

ActiveUS20110281865A1Decrease and prevent riskBiocideCompound screeningDiseasePyridine
The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and / or amelioration of kinase mediated diseases or disorders with them.
Owner:RHIZEN PHARMACEUTICALS AG +1

Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency

InactiveUS20100166806A1Adverse propertyPrevent HIV-1-induced cytotoxicityBiocideOrganic chemistryReverse transcriptaseHydroxamic acid
The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and / or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).
Owner:APHIOS

Allosteric protein kinase modulators

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.
Owner:UNIV DES SAARLANDES

Triazolo-pyridazine protein kinase modulators

The present disclosure relates to tirazalopyridazine protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
Owner:SGX PHARMA INC

Pyrazolothiazole Protein Kinase Modulators

The present invention provides pyrazolothiazole kinase modulators, methods of treating certain disease states, such as cancer, and pharmaceutical composition thereof.
Owner:SGX PHARMA INC

Methods and compositions for reducing injury to a transplanted organ

Methods for reducing injury to a transplanted mammalian organ or tissue, including inhibiting the development of graft blood vessel disease, are provided. In one form, a method includes administering compositions that include one or more PKC regulators to an organ or tissue donor and an organ or tissue recipient. Methods for decreasing or otherwise modulating an inflammatory response in a mammal are also provided. In one form, a method includes administering one or more regulators of protein kinase C to a patient in need thereof prior to, during or after an event giving rise to an inflammatory response. Methods for inhibiting, or otherwise modulating, a pro-apoptotic event are also provided. In one form, a method includes administering a therapeutically effective amount of an agonist of ε protein kinase C, and optionally an inhibitor of δ protein kinase C.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Heterocyclic kinase modulators

The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
Owner:SGX PHARMA INC

Triazolopyridazine protein kinase modulators

InactiveUS20100120739A1Reduce and inhibit kinase activityModulate kinase activityBiocideOrganic chemistryDiseaseKinase activity
The present disclosure relates to triazolopyridazine protein kinase modulators of Formula (I), methods of using these compounds to treat diseases mediated by kinase activity.
Owner:SGX PHARMA INC

Pyrazole derivatives as protein kinase modulators

The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.
Owner:ASTEX THERAPEUTICS LTD +2

Protein kinase modulators

InactiveUS20120208792A1BiocideNervous disorderFms-Like Tyrosine KinasePolymerase L
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and / or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
Owner:SENHWA BIOSCIENCES INC

Novel protein kinase modulators and therapeutic uses thereof

The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and / or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.
Owner:NOVOTYR THERAPEUTICS LTD

Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein, etc

ActiveUS20150057309A1Decrease and prevent riskBiocideOrganic chemistryDiseaseC-Met
The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and / or amelioration of c-Met kinase mediated disease or disorders with them.
Owner:RHIZEN PHARMACEUTICALS AG

Deuterated serine-threonine protein kinase modulators

InactiveUS20120129849A1Modulating protein kinase activityInhibit cell proliferationBiocideSenses disorderPolymerase LRibose
The present invention provides deuterated compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The deuterated compounds of the invention can modulate casein kinase (CK) activity and / or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such deuterated compounds as therapeutic agents.
Owner:SENHWA BIOSCIENCES INC

Pyrazole derivatives as protein kinase modulators

The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rand NR<2>R<3> and a maximum chain length of 4 atoms extending between E and NR<2>R<3>, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR<2>R<3> group and provided that the oxo group when present is located at a carbon atom a with respect to the NR<2>R<3> group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R is an aryl or heteroaryl group; and R<2>, R<3>, R<4> and R<5> are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.
Owner:ASTEX THERAPEUTICS LTD +2

Dual selective pi3 delta and gamma kinase inhibitors

The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and / or amelioration of Pi3K kinase mediated diseases or disorders with them.
Owner:RHIZEN PHARMACEUTICALS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products